Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

New generation eye drops with Cyclosporine A in the treatment of patients with severe dry eye

Poster Details

First Author: E. Mrukwa-Kominek POLAND

Co Author(s):    M. Nowak   S. Wagner   R. Kinasz              

Abstract Details

Purpose:

The aim of this presentation is to assess the effectiveness and the benefits of new generation eye drops with Cyclosporin A (Ikervis) in the treatment of severe dry eye syndrome. The availability of new generation eye drops will represent a significant progress in the management of severe dry eye patients

Setting:

Department of Ophthalmology, University Clinical Center, Medical University of Silesia, Katowice, Poland

Methods:

Five female patients was referred to the corneal unit of University Clinical Center in Katowice because of severe symptoms of dry eye. Patients received symptomatic treatment for 3-6 years, with no success. The patients were administered eye drops cyclosporine (1mg/1ml, Ikervis, Santen) once a day, one drop into each eye. There were assessed changes in: BCVA, IOP, Meibomian Gland Dysfunction, corneal staining, confocal microscopy images, Ocular Surface Disease Index (OSDI).

Results:

In all patients one-week after cyclosporine introduction the improvement in clinical state, decrease in fluorescein staining of the corneal surface and reduction of OSDI from 60 to 52 points were observed. After one month the patient quality of life improved significantly. After 3 months mean BCDVA increased from 0.6 to 0.8. Confocal microscopy revealed apparent distortions in the keratocytes arrangement, folds in the deep stroma and multiple subepithelial deposits. Mean OSDI was 38 points after 2 months.

Conclusions:

The benefits with Cyclosporin A in the new technology are its ability to improve ocular surface damage and reduce inflammation in dry eye disease patients with severe keratitis

Financial Disclosure:

One or more of the authors receives consulting fees, retainer, or contract payments from a competing company

Back to Poster listing